PureTech Health (LON:PRTC) Stock Price Up 14.6% – Should You Buy?

Shares of PureTech Health plc (LON:PRTC) traded up 14.6% during trading on Saturday . The stock traded as high as GBX 118 ($1.54) and last traded at GBX 118 ($1.54). 1,623,564 shares traded hands during mid-day trading, an increase of 54% from the average session volume of 1,056,594 shares. The stock had previously closed at GBX 103 ($1.35).

Analysts Set New Price Targets

Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 455 ($5.96) price target on shares of PureTech Health in a report on Monday, December 16th.

PureTech Health Stock Performance

The firm has a market cap of £354.45 million, a price-to-earnings ratio of -4.84 and a beta of 1.02. The stock has a 50-day moving average of GBX 135.24 and a 200-day moving average of GBX 148.08. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.